Tech Company Financing Transactions

Nimbus Therapeutics Funding Round

On 3/18/2015, Nimbus Therapeutics raised $43 million in Series B funding from Lightstone Ventures, Pfizer Venture Investments and Atlas Venture.

Transaction Overview

Company Name
Nimbus Therapeutics
Announced On
3/18/2015
Transaction Type
Venture Equity
Amount
$43,000,000
Round
Series B
Investors

Lightstone Ventures (Lead Investor) (Chris Christoffersen)

Pfizer Venture Investments (Lead Investor)

Atlas Venture (Bruce Booth)

Cascade Investment

Lilly Ventures (Steven Hall)

SR One Capital Management (Kent Gossett)

Proceeds Purpose
Nimbus plans to use the funds from the Series B round to advance its lead program, an Acetyl CoA Carboxylase (ACC) inhibitor, into clinical development, representing the first allosteric and liver-targeted inhibitor intended for the treatment of Non-alcoholic Steatohepatitis, or NASH, an increasingly common liver disease which is estimated to affect 16 million Americans. Nimbus plans to report Phase 1 data from this program later this year. Additionally, the company will continue to advance its preclinical programs of novel small molecules including those for IRAK4, Tyk2, KRas and other medically-important targets.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
130 Prospect St. 301
Cambridge, MA 02139
USA
Phone
(857) 999-2009
Website
www.nimbustx.com
Email Address
[email protected]
Overview
Nimbus Therapeutics is a biotechnology company that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development.
Profile
Nimbus Therapeutics LinkedIn Company Profile
Social Media
Nimbus Therapeutics Company Twitter Account
Company News
Nimbus Therapeutics News
Facebook
Nimbus Therapeutics on Facebook
YouTube
Nimbus Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeb Keiper
  Jeb Keiper LinkedIn Profile  Jeb Keiper Twitter Account  Jeb Keiper News  Jeb Keiper on Facebook
Chief Financial Officer
Holly Whittemore
  Holly Whittemore LinkedIn Profile  Holly Whittemore Twitter Account  Holly Whittemore News  Holly Whittemore on Facebook
Chief Scientific Officer
Peter Tummino
  Peter Tummino LinkedIn Profile  Peter Tummino Twitter Account  Peter Tummino News  Peter Tummino on Facebook
Vice President
Scott Edmondson
  Scott Edmondson LinkedIn Profile  Scott Edmondson Twitter Account  Scott Edmondson News  Scott Edmondson on Facebook
Vice President
Christine Loh
  Christine Loh LinkedIn Profile  Christine Loh Twitter Account  Christine Loh News  Christine Loh on Facebook
VP - Bus. Development
Abbas Kazimi
  Abbas Kazimi LinkedIn Profile  Abbas Kazimi Twitter Account  Abbas Kazimi News  Abbas Kazimi on Facebook
VP - Human Resources
Erin Cowhig
  Erin Cowhig LinkedIn Profile  Erin Cowhig Twitter Account  Erin Cowhig News  Erin Cowhig on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/18/2015: CafeX Communications venture capital transaction
Next: 3/18/2015: Zentila venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We report on funding rounds that are announced publicly. VC transactions on this site are derived from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.